COPD Foundation, Miami, Florida.
Respir Care. 2023 Jul;68(7):998-1012. doi: 10.4187/respcare.10876.
Long-term oxygen therapy (LTOT) is a mainstay treatment for patients with severe resting hypoxemia secondary to chronic respiratory conditions including COPD. The evidence for LTOT is based on two trials that are now several decades old but have been insufficiently revisited. Therefore, many questions remain about precisely which patients experience the most benefit from LTOT, as well as how to define that benefit. Most studies have examined LTOT's effect on longevity rather than its impact on quality of life. In addition, many challenges exist in training both clinicians and patients on best practices for LTOT and associated equipment. Reimbursement policies have reduced the kinds of equipment available to the LTOT patient community, presenting additional challenges. This paper will review the current evidence for LTOT in COPD, the challenges involved with providing optimal therapy, and potential avenues of modernizing this essential intervention.
长期氧疗（LTOT）是治疗慢性呼吸系统疾病（包括 COPD）导致严重静息低氧血症患者的主要方法。LTOT 的证据基于两项现已几十年历史的试验，但这些试验尚未得到充分重新评估。因此，关于哪些患者从 LTOT 中获益最多，以及如何定义这种获益，仍存在许多问题。大多数研究都考察了 LTOT 对寿命的影响，而不是对生活质量的影响。此外，在培训临床医生和患者有关 LTOT 及其相关设备的最佳实践方面存在许多挑战。报销政策减少了 LTOT 患者群体可获得的设备种类，这带来了额外的挑战。本文将回顾 COPD 患者 LTOT 的现有证据、提供最佳治疗的相关挑战，以及使这种基本干预现代化的潜在途径。
